Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Jumia Technologies AG - ADR — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Jumia Technologies AG - ADR trades at $6.28 (market cap $865.90M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 14.5× Jumia Technologies AG - ADR's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Jumia Technologies AG - ADR for 28 Days on average.
| HALO | JMIA | |
|---|---|---|
Market Cap | $12.58B | $865.90M |
Volume | 2,179,278 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $115.22 | $14.60 |
52-Week Low | $61.63 | $5.69 |
Typical Hold Time | 1 Days | 28 Days |
Enterprise Value | $14.49B | $831.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JMIA stock trades at $6.48, down 3.86% today, with a bearish technical outlook from moving averages. The company reported Q2 2026 revenue growth and narrowing losses, with a path to EBITDA breakeven by Q4 2026. Analyst consensus is bullish with a $12.00 price target, but the stock faces headwinds from persistent negative earnings and high valuation multiples.
The investment case hinges on JMIA's operational improvements and capital infusion, but risks include sustained cash burn and competitive pressures in African e-commerce. Upside potential exists if profitability targets are met, yet the stock remains speculative given its financial losses and volatile trading pattern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
